Ziagen is used with other antiviral medicines to treat patients who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS). Ziagen contains the active substance abacavir.
Therapeutic Indication
### Therapeutic indication Ziagen is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children. The demonstration of the benefit of Ziagen is mainly based on results of studies performed with a twice daily regimen, in treatment-naïve adult patients on combination therapy. Before initiating treatment with abacavir, screening for carriage of the HLA-B\*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B\*5701 allele.
Therapeutic Area (MeSH)
ATC Code
J05AF06
ATC Item
abacavir
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| abacavir | N/A | 阿巴卡韦 |
EMA Name
Ziagen
Medicine Name
Ziagen
Aliases
N/ANo risk management plan link.
